Loading
A phase 1/2 trial of JDQ443, Trametinib, Ribociclib in non-small-cell lung cancer and small-cell lung cancer, run by Novartis Pharmaceuticals, active and no longer recruiting.
Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation is a phase 1/2 interventional study registered as NCT05358249 by Novartis Pharmaceuticals, with 74 participants enrolled, started 2022-10-24 and due to reach its primary completion in 2026-09-30. Interventions recorded: JDQ443, trametinib, Ribociclib, cetuximab. Conditions listed: KRAS G12C Mutant Solid Tumors, Carcinoma, Non-Small Cell Lung, Carcinoma, Non-Small-Cell Lung, Non-Small Cell Lung Cancer. No results are recorded here; the registry entry is the source.
Shares JDQ443, Trametinib, Cetuximab, Novartis.
Shares JDQ443, KRAS G12C-mutant non-small-cell lung cancer, Novartis, Non-small-cell lung cancer.
Shares JDQ443, KRAS G12C-mutant colorectal cancer, KRAS G12C-mutant non-small-cell lung cancer, Novartis.
Shares JDQ443, KRAS G12C-mutant non-small-cell lung cancer, Novartis, Non-small-cell lung cancer.
Shares KRAS G12C-mutant colorectal cancer, KRAS G12C-mutant non-small-cell lung cancer, Colorectal cancer, Non-small-cell lung cancer.
Shares KRAS G12C-mutant colorectal cancer, KRAS G12C-mutant non-small-cell lung cancer, Small-cell lung cancer, Colorectal cancer.
Shares Ribociclib, Novartis, Small-cell lung cancer.
Shares Ribociclib, Trametinib, Novartis.